Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Area of Science:

• Infectious Diseases
• Antimicrobial Resistance
• Pharmacology

Background:

• Acinetobacter baumannii complex (ABC) causes severe infections like pneumonia and septic shock.
• Limited treatment options exist for ABC, particularly carbapenem-resistant strains (CRAB), due to widespread antimicrobial resistance.
• Existing drugs like polymyxin and colistin have drawbacks, including poor lung penetration and toxicity, highlighting the need for novel therapies.

Purpose of the Study:

• To review the current landscape and future pipeline of anti-infective agents targeting ABC and CRAB.
• To provide clinicians with context on emerging drugs by analyzing in vitro activity, mechanisms of action, and clinical trial data.
• To highlight the urgent need for new treatment paradigms against difficult-to-treat ABC and CRAB infections.

Main Methods:

• Literature review of in vitro activity, mechanisms of action, and clinical trial data for existing and investigational drugs.
• Analysis of commercially available agents: cefiderocol and sulbactam-durlobactam.
• Review of novel agents in Phase II and III clinical trials: BV-100, cefepime-zidebactam, zosurabalpin, and OMN6.

Main Results:

• Cefiderocol and sulbactam-durlobactam are now available for treating CRAB infections.
• Several novel anti-infectives targeting CRAB are progressing through late-stage clinical trials.
• Data on four promising novel drugs (BV-100, cefepime-zidebactam, zosurabalpin, OMN6) against ABC are discussed.

Conclusions:

• The development pipeline for CRAB infections shows promise with new agents offering alternative mechanisms.
• Understanding these emerging therapies is crucial for clinicians managing challenging Acinetobacter baumannii complex infections.
• Continued research and clinical trials are essential to combat the growing threat of antimicrobial resistance.